Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3725 USD | -3.62% | -90.76% | -92.89% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 1.57M | Sales 2025 * | 672K | Capitalization | 22.71M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -75M | EV / Sales 2024 * | 14.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 33.8 x |
P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-0.4
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.92% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -3.62% | ||
1 week | -90.76% | ||
Current month | -92.78% | ||
1 month | -92.90% | ||
3 months | -92.37% | ||
6 months | -87.58% | ||
Current year | -92.89% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.3725 | -3.62% | 3,680,139 |
24-05-09 | 0.3865 | -0.85% | 5,265,060 |
24-05-08 | 0.3898 | -7.19% | 7,701,019 |
24-05-07 | 0.42 | -19.46% | 19,067,445 |
24-05-06 | 0.5215 | -87.06% | 108,645,212 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.89% | 22.71M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- LYRA Stock